Abstract
This review describes the role of nuclear receptors in the regulation of genes involved in cholesterol transport and synthetic modulators of these receptors. Increasing the efflux of cholesterol from peripheral cells, such as lipid-laden macrophages, through a process called reverse cholesterol transport (RCT) requires HDL. Increasing the circulating levels of HDL, as well as the efficiency of the RCT process, could result in a reduction in the development of coronary artery disease and atherosclerosis. Nuclear receptors of the RXR heterodimer family have recently been shown to regulate key genes involved in HDL metabolism and reverse cholesterol transport. These include the PPARs (peroxisome proliferator activated receptors), the LXR (liver X receptor) and the farnesoid X receptor (FXR). The synthesis of specific and potent ligands for these receptors has aided in ascertaining the physiological role of these receptors as lipid sensors and the potential therapeutic utility of modulators of these receptors in dyslipidemias and cardiovascular disease.
Keywords: atherosclerotic disease, low density lipoproteins (ldl), reverse cholesterol transport (rct), coronary artery disease, peroxisome proliferator activated receptor alpha, rexinoid x receptor (rxr), phospholipid, expression
Current Topics in Medicinal Chemistry
Title: Nuclear Receptors as Potential Targets for Modulating Reverse Cholesterol Transport
Volume: 5 Issue: 3
Author(s): Patricia D. Pelton, Mona Patel and Keith T. Demarest
Affiliation:
Keywords: atherosclerotic disease, low density lipoproteins (ldl), reverse cholesterol transport (rct), coronary artery disease, peroxisome proliferator activated receptor alpha, rexinoid x receptor (rxr), phospholipid, expression
Abstract: This review describes the role of nuclear receptors in the regulation of genes involved in cholesterol transport and synthetic modulators of these receptors. Increasing the efflux of cholesterol from peripheral cells, such as lipid-laden macrophages, through a process called reverse cholesterol transport (RCT) requires HDL. Increasing the circulating levels of HDL, as well as the efficiency of the RCT process, could result in a reduction in the development of coronary artery disease and atherosclerosis. Nuclear receptors of the RXR heterodimer family have recently been shown to regulate key genes involved in HDL metabolism and reverse cholesterol transport. These include the PPARs (peroxisome proliferator activated receptors), the LXR (liver X receptor) and the farnesoid X receptor (FXR). The synthesis of specific and potent ligands for these receptors has aided in ascertaining the physiological role of these receptors as lipid sensors and the potential therapeutic utility of modulators of these receptors in dyslipidemias and cardiovascular disease.
Export Options
About this article
Cite this article as:
Pelton D. Patricia, Patel Mona and Demarest T. Keith, Nuclear Receptors as Potential Targets for Modulating Reverse Cholesterol Transport, Current Topics in Medicinal Chemistry 2005; 5 (3) . https://dx.doi.org/10.2174/1568026053544588
DOI https://dx.doi.org/10.2174/1568026053544588 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Rheumatoid Arthritis: Cardiovascular Manifestations, Pathogenesis, and Therapy
Current Pharmaceutical Design Novel Anticoagulants vs Warfarin for Stroke Prevention in Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets An Introduction to Obesity and Dementia
Current Alzheimer Research Design, Synthesis and Cytotoxicity of Chalcone Analogs Derived from 2-Phenylimino-3-phenylthiazolidin-4-one
Letters in Drug Design & Discovery Assessment of Cardiac Performance with Magnetic Resonance Imaging
Current Cardiology Reviews Cholesterol and Alzheimers Disease: Clinical and Experimental Models Suggest Interactions of Different Genetic, Dietary and Environmental Risk Factors
Current Drug Targets A Novel Finding: Macrophages Involved in Inflammation Participate in Acute Aortic Dissection Complicated with Acute Lung Injury
Current Molecular Medicine Selective Serotonin Re-Uptake Inhibitors for the Treatment of Depression in Coronary Artery Disease and Chronic Heart Failure: Evidence for Pleiotropic Effects
Cardiovascular & Hematological Agents in Medicinal Chemistry Role of Micronutrients on Subclinical Atherosclerosis Micronutrients in Subclinical Atherosclerosis
Current Pharmaceutical Design Transcranial Doppler Ultrasonography: Current Status
Current Medical Imaging Palliative Combined Percutaneous Balloon Aortic Valvuloplasty and Unprotected Left Main Stenting in End Stage Renal Disease
Current Cardiology Reviews Mechanical Circulatory Support for End-Stage Heart Failure in Repaired and Palliated Congenital Heart Disease
Current Cardiology Reviews Hybrid Docking-QSAR Studies of 1, 4-dihydropyridine-3, 5-Dicarboxamides as Potential Antitubercular Agents
Current Computer-Aided Drug Design Abeta Immunotherapy and Other Means to Remove Amyloid
Current Drug Targets - CNS & Neurological Disorders Recreational Drug Misuse and Stroke
Current Drug Abuse Reviews Drug Combinations for Dyslipidemia and Obesity Treatment in Metabolic Syndrome
Current Pharmaceutical Design Structural and Functional Characterization of a Mutant of Pseudocerastes persicus Natriuretic Peptide
Protein & Peptide Letters Device Therapies: New Indications and Future Directions
Current Cardiology Reviews Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets New Approaches to Raising the HDL Cholesterol Level
Mini-Reviews in Medicinal Chemistry